The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

Cytokinetics's aficamten outperforms metoprolol in Phase 3 heart disease trial, but FDA approval delayed to December due to ...

Bayer cuts 2,000 jobs in Q1 2025, reaching 11,000 total layoffs amid reorganization. CEO Bill Anderson reports strong pharma ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...

GSK said it is axing development of belrestotug and concluding its iTeos collaboration, which began with $625 million upfront ...

Galapagos is turning heads by reconsidering whether to do its planned spinoff, which was originally announced in January.

To­day on Post Hoc Live, Drew Arm­strong is joined by Nick Ship­ley, the for­mer top lob­by­ist for the biotech in­dus­try, ...

Andrew Witty is out as CEO of UnitedHealth Group after a tumultuous couple of years that included the shooting death of a top ...

White House drug pricing plan faces skepticism as experts question feasibility of Trump's executive order to align US prices ...

Plus, news about Neumora, Erasca, FibroGen, Tilt Biotherapeutics, Sangamo, Leap Therapeutics, Remedy Plan, Lexeo, Karyopharm, Tango Therapeutics and Humacyte.

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...